2023 proved to be another year of success across our institute. It marked four years of IMPACT this year, and in this short space of time, we’ve had growth well beyond what we anticipated.
Since our inception, we’ve more than tripled in size, and are now home to over 300 researchers. We’ve received millions in competitive grant successes, mentored the next generation of talented biomedical leaders and most importantly we’ve collectively built the success of biomedical research here at Deakin University.
Our researchers have continued to move from strength to strength, showing their ability to recover after several years of COVID-related interruptions. Yet, from this global disruption, we’ve seen a new appreciation for science come to the forefront of our minds.
Most people are unaware of the dedicated researchers spending hours in laboratories to find better treatments for infectious disease patients or conducting large-scale clinical trials with participants seeking better treatments for mental health conditions.
This team of diverse researchers specialises in mental health, clinical trials, infectious diseases research, cancer, metabolic disorders and more.
We hope you enjoy reading about the successes of our institute, as much as we’ve enjoyed being part of the story. Thank you to those who have played a role in the growth and achievements of IMPACT. We look forward to seeing what the new year will bring.
Alfred Deakin Professor Michael Berk and Professor Ken Walder
Director and Deputy Director
